Laidlaw acts as Co-Manager on the $287,500,000 Follow-On Offering for Viking Therapeutics.

View Larger Image

Laidlaw is pleased to act as Co-Manager on Vikings 287.5mm dollar offering. Laidlaw Capital Markets was the Sole Book Runner on Viking’s 27.6mm dollar IPO in 2015. VKTX is now over a one billion dollar company brought to market off the Laidlaw launchpad.

Read Article

dan2023-03-31T03:30:28-04:00

© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

© Copyright 2023 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).

Site Info

Legal

Disclosures

Contact Info

Recent Posts

Stay In Touch

Contact Info